Most people comparing semaglutide and tirzepatide want one clear answer: which one worked better? The first direct obesity trial gives us one.
FOR WEIGHT LOSS IN SURMOUNT-5, TIRZEPATIDE WORKED BETTER AND HAD FEWER GI-RELATED TREATMENT STOPS. SEMAGLUTIDE HAS A LONGER CLINICAL HISTORY.
After 72 weeks, participants taking tirzepatide lost 20.2% of their body weight on average, compared with 13.7% for semaglutide. Tirzepatide also had fewer treatment stops caused by digestive side effects. Semaglutide still has a clear advantage of its own: it has several more years of clinical use and physician familiarity.
That is the useful semaglutide vs tirzepatide comparison. Here is what the numbers and the molecules mean in plain English.
Established history or stronger head-to-head results?
Both have clinical evidence, but their strongest advantages are different.
Semaglutide
Longer clinical history
A single GLP-1 receptor agonist first approved in the U.S. in 2017.
Tirzepatide
More average weight loss
A dual GIP and GLP-1 agonist with the stronger SURMOUNT-5 result.
Practical takeaway
13.7% vs 20.2%
Tirzepatide also had fewer GI-related treatment stops in that trial.
What is the biggest difference between semaglutide and tirzepatide?
The biggest difference is simple: semaglutide targets one receptor type, while tirzepatide targets two.
- Semaglutide activates the GLP-1 receptor.
- Tirzepatide activates the GIP and GLP-1 receptors.
A receptor is a structure on a cell that receives a chemical signal. Because semaglutide activates GLP-1, it is called a single receptor agonist. Because tirzepatide activates GIP and GLP-1, it is called a dual receptor agonist.
That second GIP target is tirzepatide’s key design advantage. The FDA uses the same descriptions in its current Wegovy prescribing information and Zepbound prescribing information.
Which produced more weight loss in a direct trial?
TIRZEPATIDE PRODUCED THE GREATER AVERAGE WEIGHT LOSS IN SURMOUNT-5.
SURMOUNT-5 was the first large clinical trial designed to compare the two medicines directly for obesity. It included 751 adults with obesity but without type 2 diabetes. Participants received the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks.
| 72-week result | Tirzepatide | Semaglutide |
|---|---|---|
| Average body-weight change | −20.2% | −13.7% |
| Average waist-circumference change | −18.4 cm | −13.0 cm |
The difference was not small. Tirzepatide produced 6.5 percentage points more average weight loss and 5.4 cm more average waist reduction than semaglutide.
Read the peer-reviewed results in The New England Journal of Medicine or review the completed SURMOUNT-5 trial record.
Did tirzepatide also have fewer side effects?
The strongest accurate answer is more specific: tirzepatide had fewer GI-related treatment stops in SURMOUNT-5.
| 72-week tolerability measure | Tirzepatide | Semaglutide |
|---|---|---|
| Participants reporting any adverse event | 76.7% | 79.0% |
| Stopped because of any adverse event | 6.1% | 8.0% |
| Stopped because of gastrointestinal side effects | 2.7% | 5.6% |
The most common side effects in both groups involved the stomach or digestion. Most were mild to moderate and appeared mainly while doses were being increased. On the practical measure of whether digestive side effects made participants stop treatment, tirzepatide had the better result.
So the clean, evidence-backed conclusion is: tirzepatide produced more average weight loss and fewer GI-related treatment stops than semaglutide in this direct trial.
Why might someone still prefer semaglutide?
Semaglutide has the longer clinical track record. The FDA first approved a semaglutide medicine in 2017 and a tirzepatide medicine in 2022. Those additional years mean more clinical use, longer follow-up, and greater physician familiarity.
That makes semaglutide the more established option. Tirzepatide is the newer dual-receptor option with the stronger weight-loss result in the direct trial. Neither advantage needs to cancel out the other.
Are semaglutide and tirzepatide the same thing?
No. They are different molecules, and the names should never be exchanged on a label, COA, specification sheet, or research plan.
Consumers may recognize semaglutide as the active ingredient in Ozempic and Wegovy, and tirzepatide as the active ingredient in Mounjaro and Zepbound. Those are finished prescription brands. Certiva manufactures and supplies unbranded, lyophilized laboratory research reference materials, not those finished medicines.
For simple introductions to each molecule, read What Is Semaglutide? and Is Tirzepatide a Peptide?.
What should buyers compare in a bulk semaglutide or tirzepatide supplier?
A molecule name is only the beginning of a purchasing decision. A serious bulk peptide supplier should make the actual batch easy to verify.
Before requesting a quote, compare:
- the exact molecule and vial strength;
- a lot number that connects the vial to its COA;
- HPLC purity data and mass-spectrometry identity information;
- stocked, bulk, and custom-quantity options;
- packaging, storage, lead time, and destination requirements; and
- whether the company can answer manufacturing questions directly.
Certiva is both a peptide manufacturer and a direct supplier. We manufacture at our own facility and support stocked, bulk, wholesale, and custom-quantity inquiries. Read the difference between a peptide supplier and manufacturer, or review Certiva’s manufacturing facility.
Our five-minute peptide COA guide also shows how to check batch documents without needing a chemistry degree.
How do Certiva’s semaglutide and tirzepatide options compare?
| Research material | Available vial specifications | Standard box |
|---|---|---|
| Semaglutide | 5, 10, 15, 20, 30 and 50 mg | 10 vials |
| Tirzepatide | 5, 10, 15, 20, 30, 40, 50, 60, 80, 100 and 120 mg | 10 vials |
Bulk and custom quantities are available by inquiry. Buyers can request the current batch COA, availability, lead time, and destination-based quote before placing an order.
Need to check peptide calculation math?
Use Certiva’s free peptide reconstitution calculator to convert a labeled vial mass, liquid volume, and user-supplied reference amount into concentration, milliliters, and U-100 scale markings. It shows the formula behind the result and runs privately in the browser.
The calculator performs arithmetic only. It does not recommend a peptide, dose, schedule, or method of administration.
What do the published Certiva COAs show?
The current published 2026 reports list:
- Semaglutide: 99.599% HPLC purity
- Tirzepatide: 99.699% HPLC purity
These are batch-specific results. The important buying question is whether the report matches the lot being offered now.
View Certiva’s published COAs or open the current published semaglutide report and tirzepatide report.
The bottom line
Semaglutide’s clearest advantage is its longer clinical history. Tirzepatide’s clearest advantages are dual-receptor action, greater average weight loss, and fewer GI-related treatment stops in the direct SURMOUNT-5 comparison.
For a laboratory buyer, the next decision is not about a headline. It is about the required molecule, vial specification, quantity, matching batch COA, and delivery needs.
Compare current COAs and request a quote
Tell Certiva whether you need semaglutide, tirzepatide, or both. Include the vial strength, quantity, destination country, and documentation requirements. We will reply with current availability, applicable batch information, lead time, and a quote.
Compare semaglutide specifications · Compare tirzepatide specifications · Use the peptide calculator · See the COA process
Request current COAs + a quote →
Sources and further reading
- The New England Journal of Medicine: SURMOUNT-5 head-to-head trial
- ClinicalTrials.gov: completed SURMOUNT-5 study record
- FDA: approval years for semaglutide and tirzepatide medicines
- FDA: current Wegovy prescribing information
- FDA: current Zepbound prescribing information
Frequently asked questions
Which works better, semaglutide or tirzepatide?
FOR WEIGHT LOSS IN SURMOUNT-5, TIRZEPATIDE WORKED BETTER AND HAD FEWER GI-RELATED TREATMENT STOPS. Semaglutide has a longer clinical history.
What is the main difference between semaglutide and tirzepatide?
Semaglutide activates one receptor type, GLP-1. Tirzepatide activates two receptor types, GIP and GLP-1. That is why semaglutide is called a single receptor agonist and tirzepatide is called a dual receptor agonist.
Does tirzepatide have fewer side effects than semaglutide?
In SURMOUNT-5, tirzepatide had a slightly lower overall adverse-event rate than semaglutide, 76.7% versus 79.0%, and fewer participants stopped because of gastrointestinal side effects, 2.7% versus 5.6%. The most precise conclusion is that tirzepatide had fewer GI-related treatment stops in this trial.
Which has the longer clinical history?
Semaglutide has the longer U.S. clinical history. The FDA first approved a semaglutide medicine in 2017 and a tirzepatide medicine in 2022.
Are semaglutide and tirzepatide the same thing?
No. They are different peptide molecules. They share GLP-1 receptor activity, but tirzepatide also activates the GIP receptor.
Can I compare Certiva semaglutide and tirzepatide COAs before ordering?
Yes. Certiva publishes batch COAs and accepts requests for the current report, vial specifications, availability, lead time, and a destination-based quote before an order is placed.
What vial sizes are available for research?
Certiva lists semaglutide in 5 mg to 50 mg vials and tirzepatide in 5 mg to 120 mg vials, with 10 vials per standard box. Bulk and custom quantities are available by inquiry.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.